Medtronic plc
MDTAPI behind this page
MDT Q3 2026 request
Playground key active
/api/financials?ticker=MDT&year=2026&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2026 | Q3 2025 | YoY |
|---|---|---|---|
| Revenue | 9,017 | 8,292 | +8.7% |
Show Business Segments breakouts |
|||
| All Other Segments · Non Us | 14 | 17 | -17.6% |
| All Other Segments · Operating Segments | 32 | 32 | 0.0% |
| All Other Segments · US | 18 | 15 | +20.0% |
| Cardiovascular · Cardiac Rhythm & Heart Failure | 1,856 | 1,545 | +20.1% |
| Cardiovascular · Coronary & Peripheral Vascular | 672 | 618 | +8.7% |
| Cardiovascular · Non Us | 1,868 | 1,632 | +14.5% |
| Cardiovascular · Operating Segments | 3,457 | 3,037 | +13.8% |
| Cardiovascular · Structural Heart & Aortic | 929 | 874 | +6.3% |
| Cardiovascular · US | 1,589 | 1,405 | +13.1% |
| Diabetes · Non Us | 548 | 457 | +19.9% |
| Diabetes · Operating Segments | 796 | 694 | +14.7% |
| Diabetes · US | 248 | 236 | +5.1% |
| Medical Surgical · Acute Care & Monitoring | 519 | 476 | +9.0% |
| Medical Surgical · Non Us | 1,244 | 1,180 | +5.4% |
| Medical Surgical · Operating Segments | 2,173 | 2,072 | +4.9% |
| Medical Surgical · Surgical & Endoscopy | 1,654 | 1,596 | +3.6% |
| Medical Surgical · US | 929 | 893 | +4.0% |
| Neuroscience · Cranial & Spinal Technologies | 1,310 | 1,250 | +4.8% |
| Neuroscience · Neuromodulation | 503 | 476 | +5.7% |
| Neuroscience · Non Us | 849 | 769 | +10.4% |
| Neuroscience · Operating Segments | 2,558 | 2,458 | +4.1% |
| Neuroscience · Specialty Therapies | 746 | 732 | +1.9% |
| Neuroscience · US | 1,709 | 1,689 | +1.2% |
| Reportable segment net sales · Non Us | 4,510 | 4,038 | +11.7% |
| Reportable segment net sales · Operating Segments | 8,985 | 8,260 | +8.8% |
| Reportable segment net sales · US | 4,475 | 4,223 | +6.0% |
Show Geography breakouts |
|||
| IE | 36 | 28 | +28.6% |
| Non Us | 4,524 | 4,055 | +11.6% |
| Rest of world | 4,488 | 4,027 | +11.4% |
| Total other countries, excluding Ireland | 8,981 | 8,264 | +8.7% |
| US | 4,493 | 4,237 | +6.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 8,985 | 8,260 | +8.8% |
| Cost of Revenue | 3,261 | 2,779 | +17.3% |
Show Business Segments breakouts |
|||
| Cardiovascular · Operating Segments | 1,159 | 964 | +20.2% |
| Diabetes · Operating Segments | 332 | 284 | +16.9% |
| Medical Surgical · Operating Segments | 867 | 788 | +10.0% |
| Neuroscience · Operating Segments | 815 | 712 | +14.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 3,173 | 2,748 | +15.5% |
| Research And Development Expense Excluding Acquired In Process Cost | 722 | 675 | +7.0% |
Show Business Segments breakouts |
|||
| Cardiovascular · Operating Segments | 284 | 248 | +14.5% |
| Diabetes · Operating Segments | 109 | 108 | +0.9% |
| Medical Surgical · Operating Segments | 174 | 164 | +6.1% |
| Neuroscience · Operating Segments | 153 | 152 | +0.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 720 | 672 | +7.1% |
| Selling, General & Administrative | 2,956 | 2,717 | +8.8% |
Show Business Segments breakouts |
|||
| Cardiovascular · Operating Segments | 1,129 | 1,010 | +11.8% |
| Diabetes · Operating Segments | 300 | 266 | +12.8% |
| Medical Surgical · Operating Segments | 628 | 605 | +3.8% |
| Neuroscience · Operating Segments | 841 | 820 | +2.6% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,897 | 2,701 | +7.3% |
| Amortization Of Intangible Assets | 441 | 416 | +6.0% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 441 | 416 | +6.0% |
| Restructuring Charges Net Of Restructuring Reversals Including Cost Of Product Sold Impact | 77 | 43 | +79.1% |
| Loss Contingency Accrual Provision | 62 | 22 | +181.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 62 | 22 | +181.8% |
| Other Operating Income Expense Net | 35 | -5 | +800.0% |
| Operating Income | 1,464 | 1,646 | -11.1% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | -1 | 13 | -107.7% |
| Cardiovascular · Operating Segments | 899 | 828 | +8.6% |
| Diabetes · Operating Segments | 57 | 50 | +14.0% |
| Medical Surgical · Operating Segments | 499 | 512 | -2.5% |
| Neuroscience · Operating Segments | 737 | 762 | -3.3% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,192 | 2,151 | +1.9% |
| Other Non-Operating Income (Expense) | -121 | -72 | -68.1% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -121 | -72 | -68.1% |
| Interest Expense | 181 | 179 | +1.1% |
| Income Before Taxes | 1,404 | 1,540 | -8.8% |
| Income Tax Expense (Benefit) | 254 | 237 | +7.2% |
| Net Income | 1,150 | 1,303 | -11.7% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 6 | 9 | -33.3% |
| Parent | 1,143 | 1,294 | -11.7% |
| Retained Earnings | 1,143 | 1,294 | -11.7% |
| Net Income Loss Attributable To Noncontrolling Interest | -6 | -9 | +33.3% |
| Net Income | 1,143 | 1,294 | -11.7% |
| EPS (Basic) | 0.89 | 1.01 | -11.9% |
| EPS (Diluted) | 0.89 | 1.01 | -11.9% |
| Wtd Avg Shares (Basic) | 1,282.6 | 1,282.4 | 0.0% |
| Wtd Avg Shares (Diluted) | 1,289.5 | 1,286.2 | +0.3% |
| Operating Expenses (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1 | — | — |
| Comprehensive Income | 1,088 | 1,705 | -36.2% |
| Interest Income Expense Net | 85 | 114 | -25.4% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -13 | 4 | -425.0% |
Balance Sheet
| Metric | Q3 2026 | Q3 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,147 | 1,240 | -7.5% |
| Short-Term Investments | 7,236 | 6,682 | +8.3% |
| Accounts Receivable | 6,359 | 6,115 | +4.0% |
| Inventory | 6,309 | 5,610 | +12.5% |
| Other Assets Current | 3,020 | 2,865 | +5.4% |
| Total Current Assets | 24,071 | 22,513 | +6.9% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 7,179 | 6,593 | +8.9% |
| Goodwill | 41,892 | — | — |
Show Business Segments breakouts |
|||
| Cardiovascular | 8,037 | — | — |
| Diabetes | 2,256 | — | — |
| Medical Surgical | 19,842 | — | — |
| Neuroscience | 11,757 | — | — |
| Deferred Tax Assets | 3,967 | 3,614 | +9.8% |
| Other Non-Current Assets | 4,041 | 4,250 | -4.9% |
| Total Assets | 91,485 | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 207 | — | — |
| Cardiovascular · Operating Segments | 16,748 | — | — |
| Diabetes · Operating Segments | 4,312 | — | — |
| Medical Surgical · Operating Segments | 32,748 | — | — |
| Neuroscience · Operating Segments | 18,447 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 19,023 | — | — |
| Operating Segments | 72,255 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 10,335 | 12,184 | -15.2% |
| Current Liabilities | |||
| Debt Current | 191 | 2,622 | -92.7% |
Show Short Term Debt Type breakouts |
|||
| Commercial Paper | 140 | — | — |
| Accounts Payable | 2,569 | 2,286 | +12.4% |
| Deferred Compensation Liability Current | 2,581 | 2,281 | +13.2% |
| Accrued Income Taxes Current | 650 | 1,125 | -42.2% |
| Other Liabilities Current | 3,504 | 3,526 | -0.6% |
| Total Current Liabilities | 9,495 | 11,840 | -19.8% |
| Non-Current Liabilities | |||
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 1,191 | 1,063 | +12.0% |
| Accrued Income Taxes Noncurrent | 1,587 | 1,485 | +6.9% |
| Deferred Tax Liabilities | 365 | 452 | -19.2% |
| Other Non-Current Liabilities | 1,770 | 1,533 | +15.5% |
| Total Liabilities | 42,289 | 40,358 | +4.8% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 0.375 percent eight-year 2020 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 0.750 percent twelve-year 2020 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 1.000 percent twelve-year 2019 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 1.125 percent eight-year 2019 senior notes · Senior Notes | 1,757 | 1,563 | +12.4% |
| 1.375 percent twenty-year 2020 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 1.500 percent twenty-year 2019 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 1.625 percent thirty-year 2020 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 1.625 percent twelve-year 2019 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 1.750 percent thirty-year 2019 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 2.950 percent five-year 2025 senior notes · Senior Notes | 878 | — | — |
| 3.000 percent six-year 2022 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 3.125 percent nine-year 2022 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 3.375 percent twelve-year 2022 senior notes · Senior Notes | 1,171 | 1,042 | +12.4% |
| 3.650 percent five-year 2024 senior notes · Senior Notes | 996 | 886 | +12.4% |
| 3.875 percent twelve-year 2024 senior notes · Senior Notes | 996 | 886 | +12.4% |
| 4.000 percent thirty-year 2013 senior notes · Senior Notes | 305 | 305 | 0.0% |
| 4.150 percent nineteen-year 2024 senior notes · Senior Notes | 703 | 625 | +12.5% |
| 4.150 percent twenty-nine-year 2024 senior notes · Senior Notes | 820 | 729 | +12.5% |
| 4.200 percent twenty-year 2025 senior notes · Senior Notes | 878 | — | — |
| 4.250 percent five-year 2023 senior notes · Senior Notes | 1,000 | 1,000 | 0.0% |
| 4.375 percent twenty-year 2015 senior notes · Senior Notes | 1,932 | 1,932 | 0.0% |
| 4.500 percent ten-year 2023 senior notes · Senior Notes | 1,000 | 1,000 | 0.0% |
| 4.500 percent thirty-year 2012 senior notes · Senior Notes | 105 | 105 | 0.0% |
| 4.625 percent thirty-year 2014 senior notes · Senior Notes | 127 | 127 | 0.0% |
| 4.625 percent thirty-year 2015 senior notes · Senior Notes | 1,813 | 1,813 | 0.0% |
| 5.550 percent thirty-year 2010 senior notes · Senior Notes | 224 | 224 | 0.0% |
| 6.500 percent thirty-year 2009 senior notes · Senior Notes | 158 | 158 | 0.0% |
| 6.550 percent thirty-year 2007 CIFSA senior notes · Senior Notes | 253 | 253 | 0.0% |
| Senior Notes 2019 Due 2039, 2.250 Percent [Member] · Senior Notes | 1,171 | 1,042 | +12.4% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 27,880 | 23,985 | +16.2% |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 21,012 | 20,910 | +0.5% |
| Retained Earnings | 32,303 | 31,317 | +3.1% |
| Accumulated Other Comprehensive Income | -4,330 | -2,839 | -52.5% |
| Total Stockholders' Equity | 48,985 | 49,387 | -0.8% |
| Minority Interest | 211 | 228 | -7.5% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 49,196 | 49,615 | -0.8% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -636 | -527 | -20.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -116 | 432 | -126.9% |
| Accumulated Net Unrealized Investment Gain Loss | -1 | -102 | +99.0% |
| Accumulated Other Comprehensive Income | -4,330 | -2,839 | -52.5% |
| Accumulated Translation Adjustment | -2,630 | -4,129 | +36.3% |
| Additional Paid In Capital | 21,012 | 20,910 | +0.5% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent | -947 | 1,488 | -163.6% |
| Noncontrolling Interest | 211 | 228 | -7.5% |
| Parent | 48,985 | 49,387 | -0.8% |
| Retained Earnings | 32,303 | 31,317 | +3.1% |
| Total Liabilities & Equity | 91,485 | 89,973 | +1.7% |
Cash Flow Statement
| Metric | YTD Q3 2026 | YTD Q3 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 2,242 | 2,021 | +10.9% |
| Provision For Doubtful Accounts | 102 | 96 | +6.2% |
| Deferred Income Taxes And Tax Credits | 59 | -81 | +172.8% |
| Stock-Based Compensation | 362 | 340 | +6.5% |
| Other Non-Cash Items | 280 | 14 | +1900.0% |
| Increase Decrease In Accounts And Notes Receivable | 87 | -184 | +147.3% |
| Change in Inventory | -803 | -478 | -68.0% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -77 | -157 | +51.0% |
| Increase Decrease In Other Operating Capital Net | -1,074 | -685 | -56.8% |
| Net Cash from Operations | 4,757 | 4,516 | +5.3% |
| Change in Deferred Revenue (YTD) | — | — | — |
Show Geography breakouts |
|||
| IT | 39 | — | — |
| Investing Activities | |||
| Capital Expenditures | -1,416 | -1,400 | -1.1% |
| Payments To Acquire Investments | -6,572 | -6,093 | -7.9% |
| Proceeds From Sale Maturity And Collections Of Investments | 5,982 | 6,255 | -4.4% |
| Other Investing Activities | -10 | -111 | +91.0% |
| Net Cash from Investing | -2,017 | -1,447 | -39.4% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | 173 | -1,070 | +116.2% |
| Proceeds From Issuance Of Long Term Debt | 1,747 | 3,209 | -45.6% |
| Repayments Of Long Term Debt | -2,930 | — | — |
| Payments Of Dividends Common Stock | -2,731 | -2,692 | -1.4% |
| Proceeds From Issuance Or Sale Of Equity | 419 | 400 | +4.8% |
| Share Repurchases | -600 | -2,961 | +79.7% |
| Proceeds From Payments For Other Financing Activities | 60 | 96 | -37.5% |
| Net Cash from Financing | -3,863 | -3,018 | -28.0% |
| Supplemental | |||
| Income Taxes Paid | 1,598 | 1,515 | +5.5% |
| Interest Paid | 573 | 567 | +1.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 52 | -95 | +154.7% |
| Net Change in Cash | -1,072 | -44 | -2336.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,147 | 1,240 | -7.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.